Trial Details
RecruitingBasic Information
| Clinical ID | c2532 |
|---|---|
| Identifier | DRKS00019082 |
| Trial Title | Analysis of clinical, genetical, immunological and microbial factors in IBD patients to identify new prognostic and predictive factors to further optimize and personalize IBD management - The SIGMOID Study |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | K50.1_Ulcerative colitis K50 K51;Crohn disease [regional enteritis];Ulcerative colitis |
| Interventions | Group 1: IBD (inflammatory bowel disease) patients under Infliximab therapy Group 2: IBD patients under Vedolizumab therapy Group 3: IBD patients under Ustekinumab therapy |
Participant Information
| Sponsor | Medizinische Hochschule Hannover |
|---|---|
| City | - |
| Country/Region | Germany |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | observational |
|---|---|
| Phase | Not Available |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |